GlassScriptPhysician profile
Jason M Sugar
NPI 1558572651
$5,994.07
in general payments reported to CMS, 2019-2025
15 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.84 · 2020: $94.11 · 2022: $54.10 · 2023: $2,587 · 2024: $1,369 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,896 · Travel and Lodging: $2,717 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,896.39 |
| Travel and Lodging | $2,717.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gastrogpo, LLC | $2,368.00 | 2023 | |
| Medtronic, INC. | $1,262.35 | 2023-2025 | Gi Genius |
| Abbvie INC. | $883.73 | 2020-2025 | |
| Janssen Biotech, INC. | $472.53 | 2024-2025 | Tremfya |
| Pfizer INC. | $282.89 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.03 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $224.64 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $54.67 | 2025 | |
| Celltrion USA INC. | $53.85 | 2024 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $46.46 | 2024-2025 | Eohilia |
| Regeneron Healthcare Solutions, INC. | $32.46 | 2025 | Dupixent |
| Lilly USA, LLC | $27.61 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $21.06 | 2025 | |
| Novo Nordisk INC | $18.95 | 2025 | Wegovy |
| Gilead Sciences, INC. | $17.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,464.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Sugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.